文献速递心外重症与机械循环支持

iVAS微创可走动反搏心脏辅助系统首次人体试验

The first-in-human experience with a minimally invasive, ambulatory, counterpulsation heart assist system for advanced congestive heart failure.
PubMed 文献 · J Heart Lung Transplant · 2017-11-10

主要终点为30天无卒中生存或成功移植。结果显示无死亡及血栓栓塞事件,所有患者均接受移植,提示iVAS具有良好风险收益比。

要点

  • iVAS经锁骨下动脉置入,微创可走动,用于恢复、BTT或延长药物治疗。
  • 13例治疗患者无术中并发症,无死亡及血栓栓塞事件,均成功移植。
  • 术后并发症包括胸膜炎/心包炎1例和神经病变2例,无术中输血。

核心结论

  • iVAS首次人体试验显示高成功率及良好风险收益比,可标准化置入并提供血流动力学支持。

主要发现

  • 植入时平均年龄58±6.7岁,85%为男性,28%为缺血性心肌病,INTERMACS 2级3例、3级9例、4级1例。
  • 平均左室射血分数22%,左室舒张末内径7.13 mm,69%有中度或重度二尖瓣反流。
  • 无术中并发症,植入后ICU停留6±6天,所有患者在32±21天后接受移植。
  • 无死亡或血栓栓塞事件,1例需升级机械支持,术后并发症包括胸膜炎/心包炎1例和神经病变2例。
  • 无术中输血需求。

关键数值与推荐

  • 主要终点为移植后生存或无卒中生存至30天。

临床怎么用

  • iVAS可经标准化方法成功置入,提供血流动力学支持,可短暂中断并允许走动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The intravascular ventricular assist system (iVAS) is a new, minimally invasive, ambulatory counterpulsation heart assist system delivered via the subclavian artery and powered by a portable driver. It is designed for recovery, bridge to transplantation (BTT) or for prolonging medical therapy. We report the first-in-human (FIH) experience with iVAS. METHODS: This is a prospective, non-randomized single arm, U.S. Food and Drug Administration (FDA)-approved early feasibility trial in patients listed for cardiac transplantation. The primary end-point was survival to transplant or stroke-free survival at 30 days. RESULTS: Fourteen patients were enrolled and 13 (92.8%) were treated with iVAS. At time of implant, the average age was 58 ± 6.7 years; 85% were male; 28% had ischemic cardiomyopathy; and 3 were Interagency Registry for Mechanically Assisted Devices (INTERMACS) Level 2, 9 were Level 3, and 1 was Level 4. The mean left ventricular ejection fraction was 22%, left ventricular internal diameter diastole was 7.13 mm, and 69% had moderate or severe mitral regurgitation. There were no intra-operative complications. Intensive care unit stay after implant was 6 ± 6 days. All patients were transplanted after 32 ± 21 days. There were no deaths or thromboembolic events: 1 patient required escalation of mechanical support, and post-implant complications included pleuritis/pericarditis (n = 1) and neuropathy (n = 2). No intra-operative blood transfusions were required. CONCLUSIONS: This study demonstrates a high rate of successful outcomes with an excellent risk-to-benefit profile. This FIH experience reveals that the iVAS can be successfully inserted in a standardized approach, provide hemodynamic support, can be interrupted for short periods, and allows for ambulation. A multicenter trial to investigate effectiveness and safety is warranted.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Jeevanandam V, Song T, Onsager D, et al. The first-in-human experience with a minimally invasive, ambulatory, counterpulsation heart assist system for advanced congestive heart failure. J Heart Lung Transplant. 2017. PMID: 29132918. doi:10.1016/j.healun.2017.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。